An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors
OPEN TO ACCRUAL
I/II
NCT05329103
hsafran@BrownHealth.org
